Q-omics provides the consensus-scored N4BP3 profile across patient tissues and cancer cell-line models. N4BP3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, N4BP3 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, N4BP3 RNA expression shows 19,762 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where N4BP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for N4BP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes N4BP3 survival associations across molecular data types. N4BP3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible N4BP3 RNA expression–survival associations across cancer types. High N4BP3 expression shows unfavorable associations in ACC, LIHC, OV, LUSC and UVM, but favorable associations in HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for N4BP3 RNA expression.
This table summarizes N4BP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for N4BP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. N4BP3 shows lower tumor expression in HNSC and KIRC and higher tumor expression in LIHC, THCA, BRCA and COAD. The HNSC box plot shows higher N4BP3 RNA expression in normal versus tumor tissue (log2 FC = −1.275, t-test p < 0.001).
This table shows molecular features associated with N4BP3 in patient tissues and cancer cell lines. In patient samples, N4BP3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, N4BP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
